Telix's (ASX:TLX) first patient dosed for bladder cancer study

Latest Company News - Finance News Network

English - December 21, 2021 04:03 - 1000 KB
Business News News Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Worley (ASX:WOR) receives services contract by Imperial Oil

Next Episode: Charter Hall (ASX:CHC) buys 50% stake in Paradice

21 Dec 2021 - Telix Pharmaceuticals' (ASX:TLX) first patient has been dosed in a Phase I study of TLX250-CDx in patients with non-muscle invasive bladder cancer at an institute in France.